Journal
TRENDS IN BIOCHEMICAL SCIENCES
Volume 33, Issue 9, Pages 426-434Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2008.06.005
Keywords
-
Categories
Funding
- Agence Nationale de la Recherche [R0651ONS]
- Association de Langue Francaise pour l'Etude do Diabete et des Maladies Metaboliques
Ask authors/readers for more resources
Gain-of-function mutations within proprotein convertase subtilisin kexin type 9 (PCSK9) are linked to familial autosomal dominant hypercholesterolaemia, a disease characterized by elevated plasma concentrations of cholesterol associated with low-density lipoproteins (LDLs). Conversely, PCSK9 loss-of-function mutations result in low levels of LDL cholesterol (LDLC) and protect against coronary heart disease. Although compelling evidence indicates that PCSK9 impairs the LDLR pathway, its role in cholesterol metabolism remains incompletely defined. In the past two years, several new biochemical findings, including the PCSK9 crystal structure and the identification of several transcriptional repressors, were reported. Moreover, new clinical and epidemiological data have revealed the correlation between plasma PCSK9 concentrations and LDLC levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available